Literature DB >> 7916375

Loss of non-phosphorylated neurofilament immunoreactivity, with preservation of tyrosine hydroxylase, in surviving substantia nigra neurons in Parkinson's disease.

W P Gai1, J C Vickers, P C Blumbergs, W W Blessing.   

Abstract

The distribution of neurofilament immunoreactivity in the substantia nigra was examined by immunohistochemistry in five patients dying with Parkinson's disease and six control patients dying without neurological disease. In controls, pigmented neurons in the substantia nigra were intensively labelled by SMI32, a monoclonal antibody to non-phosphorylated neurofilament protein. In the substantia nigra from patients who had Parkinson's disease, there was a pronounced reduction of SMI32 labelling intensity in surviving pigmented neurons. By contrast, tyrosine hydroxylase immunoreactivity in surviving pigmented neurons was normal. SMI32 labelling was normal in regions of the brainstem not affected by the neuropathological process of Parkinson's disease. Findings with either antibodies to phosphorylated neurofilament, or enzymatic dephosphorylation followed by SMI32 labelling, indicated that loss of SMI32 immunostaining in Parkinson's disease was not due to masking of the neurofilament epitopes by phosphorylation. Our results indicate that neurofilament proteins are particularly likely to be disrupted or destroyed by the neuropathological process of Parkinson's disease. Nevertheless, the normal appearance of tyrosine hydroxylase indicates that protein synthesising systems may be intact in surviving neurons. Loss of neurofilament immunoreactivity may prove a sensitive neuropathological marker for characterisation of degenerating neurons in Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7916375      PMCID: PMC1073124          DOI: 10.1136/jnnp.57.9.1039

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  34 in total

1.  Novel monoclonal antibodies provide evidence for the in situ existence of a nonphosphorylated form of the largest neurofilament subunit.

Authors:  V M Lee; M J Carden; J Q Trojanowski
Journal:  J Neurosci       Date:  1986-03       Impact factor: 6.167

2.  Reaction of Lewy bodies with antibodies to phosphorylated and non-phosphorylated neurofilaments.

Authors:  L S Forno; L A Sternberger; N H Sternberger; A M Strefling; K Swanson; L F Eng
Journal:  Neurosci Lett       Date:  1986-03-14       Impact factor: 3.046

3.  The structure, biochemical properties, and immunogenicity of neurofilament peripheral regions are determined by phosphorylation state.

Authors:  M J Carden; W W Schlaepfer; V M Lee
Journal:  J Biol Chem       Date:  1985-08-15       Impact factor: 5.157

4.  The distribution of phosphorylation sites among identified proteolytic fragments of mammalian neurofilaments.

Authors:  J P Julien; W E Mushynski
Journal:  J Biol Chem       Date:  1983-03-25       Impact factor: 5.157

5.  Lewy bodies of Parkinson's disease contain neurofilament antigens.

Authors:  J E Goldman; S H Yen; F C Chiu; N S Peress
Journal:  Science       Date:  1983-09-09       Impact factor: 47.728

6.  Monoclonal antibodies distinguish phosphorylated and nonphosphorylated forms of neurofilaments in situ.

Authors:  L A Sternberger; N H Sternberger
Journal:  Proc Natl Acad Sci U S A       Date:  1983-10       Impact factor: 11.205

7.  A monoclonal antibody to non-phosphorylated neurofilament protein marks the vulnerable cortical neurons in Alzheimer's disease.

Authors:  J H Morrison; D A Lewis; M J Campbell; G W Huntley; D L Benson; C Bouras
Journal:  Brain Res       Date:  1987-07-28       Impact factor: 3.252

8.  Monoclonal antibodies distinguish several differentially phosphorylated states of the two largest rat neurofilament subunits (NF-H and NF-M) and demonstrate their existence in the normal nervous system of adult rats.

Authors:  V M Lee; M J Carden; W W Schlaepfer; J Q Trojanowski
Journal:  J Neurosci       Date:  1987-11       Impact factor: 6.167

9.  Senile plaques are located between apical dendritic clusters.

Authors:  K S Kosik; J Rogers; N W Kowall
Journal:  J Neuropathol Exp Neurol       Date:  1987-01       Impact factor: 3.685

10.  Identification of the major multiphosphorylation site in mammalian neurofilaments.

Authors:  V M Lee; L Otvos; M J Carden; M Hollosi; B Dietzschold; R A Lazzarini
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

View more
  6 in total

1.  Altered neurofilament protein expression in the lateral vestibular nucleus in Parkinson's disease.

Authors:  Thomas P Wellings; Alan M Brichta; Rebecca Lim
Journal:  Exp Brain Res       Date:  2017-09-19       Impact factor: 1.972

2.  AS601245, a c-Jun NH2-terminal kinase (JNK) inhibitor, reduces axon/dendrite damage and cognitive deficits after global cerebral ischaemia in gerbils.

Authors:  S Carboni; U Boschert; P Gaillard; J-P Gotteland; J-Y Gillon; P-A Vitte
Journal:  Br J Pharmacol       Date:  2007-11-19       Impact factor: 8.739

Review 3.  Beyond muscles: The untapped potential of creatine.

Authors:  Lisa A Riesberg; Stephanie A Weed; Thomas L McDonald; Joan M Eckerson; Kristen M Drescher
Journal:  Int Immunopharmacol       Date:  2016-01-08       Impact factor: 4.932

4.  Neurofilament proteins in Y-cells of the cat lateral geniculate nucleus: normal expression and alteration with visual deprivation.

Authors:  M E Bickford; W Guido; D W Godwin
Journal:  J Neurosci       Date:  1998-08-15       Impact factor: 6.167

5.  Elevated alpha-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson's disease.

Authors:  Jan Gründemann; Falk Schlaudraff; Olga Haeckel; Birgit Liss
Journal:  Nucleic Acids Res       Date:  2008-03-10       Impact factor: 16.971

6.  Iron is increased in the brains of ageing mice lacking the neurofilament light gene.

Authors:  James C Vickers; Anna E King; Graeme H McCormack; Aidan D Bindoff; Paul A Adlard
Journal:  PLoS One       Date:  2019-10-23       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.